Yao X - Search Results

1

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.

Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, Fang J. Yao X, et al. Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8. Breast Cancer Res Treat. 2015. PMID: 26253944

2

An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.

Li H, Yu C, Jiang J, Huang C, Yao X, Xu Q, Yu F, Lou L, Fang J. Li H, et al. Among authors: yao x. Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6. Cancer Biol Ther. 2016. PMID: 26853765 Free PMC article.

3

Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.

Li D, Xie K, Zhang L, Yao X, Li H, Xu Q, Wang X, Jiang J, Fang J. Li D, et al. Among authors: yao x. Cancer Lett. 2016 Jul 28;377(2):164-73. doi: 10.1016/j.canlet.2016.04.036. Epub 2016 Apr 26. Cancer Lett. 2016. PMID: 27130666

4

Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.

Li Z, Wang M, Yao X, Li H, Li S, Liu L, Yu D, Li X, Fang J, Huang C. Li Z, et al. Among authors: yao x. Int Immunopharmacol. 2018 Sep;62:299-308. doi: 10.1016/j.intimp.2018.06.034. Epub 2018 Jul 23. Int Immunopharmacol. 2018. PMID: 30048860

5

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.

Li Z, Wang M, Yao X, Luo W, Qu Y, Yu D, Li X, Fang J, Huang C. Li Z, et al. Among authors: yao x. Target Oncol. 2019 Feb;14(1):93-105. doi: 10.1007/s11523-018-0616-8. Target Oncol. 2019. PMID: 30635821

6

Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.

Li Z, Wang M, Yu D, Luo W, Fang J, Huang C, Yao X. Li Z, et al. Among authors: yao x. Cancer Chemother Pharmacol. 2019 Jul;84(1):61-72. doi: 10.1007/s00280-019-03848-9. Epub 2019 Apr 29. Cancer Chemother Pharmacol. 2019. PMID: 31037333

7

A fusion fragment from Flt-1 and KDR, acted as VEGF decoy receptor and exhibited anti-tumor function.

Li ZL, Yao XJ, Liu WF, Chen GJ. Li ZL, et al. Biotechnol Lett. 2010 Nov;32(11):1609-13. doi: 10.1007/s10529-010-0342-5. Epub 2010 Jul 6. Biotechnol Lett. 2010. PMID: 20607359

8

Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.

Zhao Q, Chen X, Hou Y, Jiang J, Zhong W, Yao X, Wang W, Li L, Fang J, Zhang F, Hu P. Zhao Q, et al. Among authors: yao x. J Clin Pharmacol. 2016 Aug;56(8):948-59. doi: 10.1002/jcph.686. Epub 2016 Feb 22. J Clin Pharmacol. 2016. PMID: 26634642 Clinical Trial.

9

Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.

Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P. Chen X, et al. Among authors: yao x. Br J Clin Pharmacol. 2016 Jul;82(1):41-52. doi: 10.1111/bcp.12908. Epub 2016 Apr 7. Br J Clin Pharmacol. 2016. PMID: 26917504 Free PMC article. Clinical Trial.

10

Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.

Chen X, Hou Y, Jiang J, Zhao Q, Zhong W, Wang W, Yao X, Li L, Fang J, Zhang F, Hu P. Chen X, et al. Among authors: yao x. Clin Pharmacokinet. 2014 Nov;53(11):1033-44. doi: 10.1007/s40262-014-0175-9. Clin Pharmacokinet. 2014. PMID: 25179916 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,400 results

Search Page

Filters